Synovics Pharmaceuticals, Inc.
SYVC
$0.00
$0.000.00%
OTC PK
| 07/31/2009 | 04/30/2009 | 01/31/2009 | 10/31/2008 | 07/31/2008 | |
|---|---|---|---|---|---|
| Revenue | 1.58M | 2.81M | 6.84M | 7.87M | 7.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58M | 2.81M | 6.84M | 7.87M | 7.72M |
| Cost of Revenue | 2.16M | 2.78M | 4.50M | 5.19M | 4.71M |
| Gross Profit | -579.80K | 27.90K | 2.34M | 2.68M | 3.01M |
| SG&A Expenses | 1.07M | 1.70M | 2.76M | 2.09M | 3.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.44M | 4.90M | 7.47M | 7.60M | 8.49M |
| Operating Income | -1.86M | -2.09M | -633.80K | 265.50K | -770.70K |
| Income Before Tax | -2.02M | -2.59M | -1.10M | 670.30K | 489.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.02M | -2.59M | -1.10M | 670.30K | 489.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.02M | -2.59M | -1.10M | 670.30K | 489.70K |
| EBIT | -1.86M | -2.09M | -633.80K | 265.50K | -770.70K |
| EBITDA | -1.64M | -1.96M | -478.40K | 438.00K | -616.80K |
| EPS Basic | -0.07 | -0.09 | -0.04 | 0.03 | 0.02 |
| Normalized Basic EPS | -0.04 | -0.06 | -0.02 | 0.02 | -0.05 |
| EPS Diluted | -0.07 | -0.09 | -0.04 | 0.03 | 0.01 |
| Normalized Diluted EPS | -0.04 | -0.06 | -0.02 | 0.02 | -0.03 |
| Average Basic Shares Outstanding | 29.89M | 28.66M | 28.34M | 25.96M | 28.48M |
| Average Diluted Shares Outstanding | 29.89M | 28.66M | 28.34M | 25.96M | 43.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |